Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Krailo

Showing results (111-120 of 161) with videos related to

Pageof 17
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 12, 2015
Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology GroupHolly J Meany, Nita L Seibel, Mark Krailo, et al.
Pediatric Blood & Cancer|April 23, 2014
HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology studySarah Gorlick, Donald A Barkauskas, Mark Krailo, et al.
JAMA Network Open|March 27, 2026
Sociodemographics and Attrition in Children With Osteosarcoma Enrolled in the AOST0331 Clinical TrialDaniel J Zheng, Natalie DelRocco, Ruxu Han, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2019
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology GroupLisa M Kopp, Suman Malempati, Mark Krailo, et al.
Blood|October 11, 2007
Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology GroupHisaki Fujii, Geoff Cuvelier, Kevin She, et al.
Cancer|November 13, 2014
Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survivalJason U Tilan, Mark Krailo, Donald A Barkauskas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2014
Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology GroupDeborah F Billmire, John W Cullen, Frederick J Rescorla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group StudyNajat C Daw, Wayne L Furman, Clinton F Stewart, et al.
Pediatric Blood & Cancer|September 15, 2025
Outcome of Children With Intermediate-Risk Extracranial Malignant Germ Cell Tumors by Response Status at the End of Induction Chemotherapy: A Report From the Children's Oncology GroupAdriana Fonseca, Doojduen Villaluna, Mark Krailo, et al.
Cancer|October 20, 2020
Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International ConsortiumFurqan Shaikh, Daniel Stark, Adriana Fonseca, et al.
Pageof 17

Showing results (111-120 of 161) with videos related to

Sort By:
Pageof 17
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 12, 2015
Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology GroupHolly J Meany, Nita L Seibel, Mark Krailo, et al.
Pediatric Blood & Cancer|April 23, 2014
HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology studySarah Gorlick, Donald A Barkauskas, Mark Krailo, et al.
JAMA Network Open|March 27, 2026
Sociodemographics and Attrition in Children With Osteosarcoma Enrolled in the AOST0331 Clinical TrialDaniel J Zheng, Natalie DelRocco, Ruxu Han, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2019
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology GroupLisa M Kopp, Suman Malempati, Mark Krailo, et al.
Blood|October 11, 2007
Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology GroupHisaki Fujii, Geoff Cuvelier, Kevin She, et al.
Cancer|November 13, 2014
Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survivalJason U Tilan, Mark Krailo, Donald A Barkauskas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2014
Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology GroupDeborah F Billmire, John W Cullen, Frederick J Rescorla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group StudyNajat C Daw, Wayne L Furman, Clinton F Stewart, et al.
Pediatric Blood & Cancer|September 15, 2025
Outcome of Children With Intermediate-Risk Extracranial Malignant Germ Cell Tumors by Response Status at the End of Induction Chemotherapy: A Report From the Children's Oncology GroupAdriana Fonseca, Doojduen Villaluna, Mark Krailo, et al.
Cancer|October 20, 2020
Outcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International ConsortiumFurqan Shaikh, Daniel Stark, Adriana Fonseca, et al.
Pageof 17